A Phase 2/3 interventional study of E/C/F/TAF in HIV, sponsored by Gilead Sciences. Completed at 7 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \< 18 years of age.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Note: participants from Gilead Study GS-US-162-0112 were allowed to roll over into this Study GS-US-292-1515 even if they were 18 years or older at the time of screening.
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks. After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country.
Drug: E/C/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
Also known as: Genvoya®
Incidence of Treatment-Emergent Serious Adverse Events
The percentage of participants experiencing any treatment-emergent serious adverse event was summarized.
Time frame: Up to Week 48
Incidence of Treatment-Emergent Adverse Events
The percentage of participants experiencing any treatment-emergent adverse event was summarized.
Time frame: Up to Week 48
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4 Cell Count at Week 24
Time frame: Baseline; Week 24
Change From Baseline in CD4 Cell Count at Week 48
Time frame: Baseline; Week 48
Change From Baseline in CD4 Percentage at Week 24
Time frame: Baseline; Week 24
Change From Baseline in CD4 Percentage at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in South Africa and the United States. The first participant was screened on 03 December 2014. The last study visit occurred on 23 October 2017.
| Milestone | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Started | 50 | 10 |
| Completed | 46 | 10 |
| Not completed | 4 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
The percentage of participants experiencing any treatment-emergent serious adverse event was summarized.
| percentage of participants | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Incidence of Treatment-Emergent Serious Adverse Events | 4.0 | 0 |
The percentage of participants experiencing any treatment-emergent adverse event was summarized.
| percentage of participants | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | 92.0 | 100.0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis) | 96.0 (86.3 to 99.5) | 100.0 (69.2 to 100.0) |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis) | 90.0 (78.2 to 96.7) | 100.0 (69.2 to 100.0) |
| cells/µL | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 24 | -72 ± 189.8 | -85 ± 245.9 |
| cells/µL | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 48 | -43 ± 201.1 | -41 ± 143.0 |
| percentage | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Change From Baseline in CD4 Percentage at Week 24 | -0.6 ± 5.46 | -0.6 ± 5.46 |
| percentage | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Change From Baseline in CD4 Percentage at Week 48 | -0.1 ± 3.95 | -1.1 ± 7.29 |
Collected over Up to 128 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF (12 - 17 Years of Age) | 1/50 (2%) | 3/50 (6%) | 42/50 (84%) |
| E/C/F/TAF (≥ 18 Years of Age) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| VomitingGastrointestinal disorders | 1/50 | 0/10 |
| ElectrocutionGeneral disorders | 1/50 | 0/10 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/50 | 0/10 |
| Event | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/50 | 6/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/50 | 5/10 |
| Nasal obstructionRespiratory, thoracic and mediastinal disorders | 3/50 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 7/50 | 2/10 |
| Oral herpesInfections and infestations | 1/50 | 2/10 |
| HeadacheNervous system disorders | 6/50 | 2/10 |
| VomitingGastrointestinal disorders | 8/50 | 1/10 |
| Viral upper respiratory tract infectionInfections and infestations | 7/50 | 0/10 |
| Vitamin D decreasedInvestigations | 7/50 | 0/10 |
| AcneSkin and subcutaneous tissue disorders | 6/50 | 0/10 |
Safety Analysis Set: participants who were enrolled in the study and received at least 1 dose of study drug.
| Age, Continuous(years) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Mean | 15 ± 1.6 | 19 ± 1.2 | 16 ± 2.2 |
| Sex: Female, Male(Participants) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Female | 32 | 3 | 35 |
| Male | 18 | 7 | 25 |
| Ethnicity (NIH/OMB)(Participants) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 49 | 10 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Black | 49 | 9 | 58 |
| White | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
| Region of Enrollment(Participants) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| United States | 8 | 0 | 8 |
| South Africa | 42 | 10 | 52 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| < 50 copies/mL | 49 | 9 | 58 |
| ≥ 50 copies/mL | 1 | 1 | 2 |
| CD4 Cell Count(cells/µL) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Mean | 753 ± 222.5 | 776 ± 179.9 | 757 ± 214.8 |
| CD4 Percentage(percentage) | E/C/F/TAF (12 - 17 Years of Age) | E/C/F/TAF (≥ 18 Years of Age) | Total |
|---|---|---|---|
| Mean | 34.3 ± 6.72 | 35.9 ± 6.53 | 34.6 ± 6.66 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Dec 2014 to primary completion in Nov 2016, 23 months.
Results were first posted in Feb 2018, 1 year 3 months after primary completion. A results delay was requested in Oct 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide